Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Prostatic Neoplasms 56Breast Neoplasms 49Lung Neoplasms 31Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 14Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Adenocarcinoma of Lung 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Triple Negative Breast Neoplasms 3Advanced Non-Small Cell Lung Cancer 3Adenocarcinoma, Bronchiolo-Alveolar 3Solid Tumor 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Inflammatory Breast Neoplasms 2Hormone Refractory Prostate Cancer 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

pertuzumab 1pegfilgrastim 1Trastuzumab 1Paclitaxel 1Hydralazine 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Locally Advanced Breast Cancer × Docetaxel × Clear all
NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
7 enrolled 10 charts
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡